DE69739870D1 - Verbesserte adenovirusvektoren - Google Patents

Verbesserte adenovirusvektoren

Info

Publication number
DE69739870D1
DE69739870D1 DE69739870T DE69739870T DE69739870D1 DE 69739870 D1 DE69739870 D1 DE 69739870D1 DE 69739870 T DE69739870 T DE 69739870T DE 69739870 T DE69739870 T DE 69739870T DE 69739870 D1 DE69739870 D1 DE 69739870D1
Authority
DE
Germany
Prior art keywords
vectors
deleted
adenoviral
improved
gutted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739870T
Other languages
English (en)
Inventor
Jeffrey S Chamberlain
Andrea Amalfitano
Michael A Hauser
Rajendra Kumar-Singh
Dennis J Hartigan-O'connor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Application granted granted Critical
Publication of DE69739870D1 publication Critical patent/DE69739870D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69739870T 1996-10-23 1997-10-23 Verbesserte adenovirusvektoren Expired - Lifetime DE69739870D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/735,609 US5994132A (en) 1996-10-23 1996-10-23 Adenovirus vectors
PCT/US1997/019541 WO1998017783A1 (en) 1996-10-23 1997-10-23 Improved adenovirus vectors

Publications (1)

Publication Number Publication Date
DE69739870D1 true DE69739870D1 (de) 2010-06-17

Family

ID=24956492

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739870T Expired - Lifetime DE69739870D1 (de) 1996-10-23 1997-10-23 Verbesserte adenovirusvektoren

Country Status (6)

Country Link
US (5) US5994132A (de)
EP (1) EP0935648B1 (de)
AT (1) ATE466931T1 (de)
AU (1) AU5152998A (de)
DE (1) DE69739870D1 (de)
WO (1) WO1998017783A1 (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US20060110798A1 (en) * 1995-06-07 2006-05-25 Graham Frank L Cells expressing recombinase useful for adenovirus vector production and control of gene expression
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
JP2002528056A (ja) * 1998-08-28 2002-09-03 デューク・ユニバーシティー ＩＶａ２、１００Ｋ及び／又は末端前タンパク質配列における欠失型アデノウイルス
WO2000042208A1 (en) * 1999-01-14 2000-07-20 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
WO2000077256A1 (en) * 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 48 human secreted proteins
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
AU1453501A (en) * 1999-11-10 2001-06-06 Genzyme Corporation Ptp/dna polymerase cell line as packaging cell line for minimal adenoviral vectors
EP1238091A2 (de) * 1999-12-14 2002-09-11 Genovo, Incorporated Verfahren und zusammensetzungen zur herstellung von replicationsunfähigen adenovirus
US6867022B1 (en) 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US6562955B2 (en) * 2000-03-17 2003-05-13 Tosoh Corporation Oligonucleotides for detection of Vibrio parahaemolyticus and detection method for Vibrio parahaemolyticus using the same oligonucleotides
DE60139394D1 (de) 2000-04-28 2009-09-10 Asklepios Biopharmaceutical In Für das dystrophin-minigen kodierende dna-sequenzen und verfahren zu deren verwendung
ES2276788T3 (es) 2000-05-10 2007-07-01 Sanofi Pasteur Limited Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US7125549B2 (en) * 2000-05-31 2006-10-24 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
DE60130465T2 (de) * 2000-07-14 2008-06-12 The Regents Of The University Of Michigan, Ann Arbor Mutierte muskelspezifische enhancer
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6852323B2 (en) * 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
EP1320620B1 (de) 2000-09-25 2015-01-21 The Regents Of The University Of Michigan Herstellung viraler vektoren
GB2368064B (en) * 2000-09-30 2002-11-13 Imp Cancer Res Tech DNA Element and Associated Protein
US6916635B2 (en) * 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
US6593145B2 (en) 2001-03-07 2003-07-15 The Texas A&M University System Density gradient solutions of metal ion chelate complexes
ES2328796T3 (es) 2001-03-14 2009-11-18 Myriad Genetics, Inc. Interaccion tsg101-gag y uso de la misma.
JP2004532039A (ja) 2001-03-26 2004-10-21 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ヘルパー依存性アデノウイルスベクター系およびその系の使用方法
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
US7449562B2 (en) * 2001-06-29 2008-11-11 Novartis Ag PERV screening method and use thereof
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
WO2003010306A1 (en) * 2001-07-23 2003-02-06 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
AU2002337892A1 (en) * 2001-10-18 2003-04-28 Aventis Pharmaceuticals Inc. Vectors for expressing multiple transgenes
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
EP1308517A1 (de) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vektoren für die Expression von mehrere Transgenen
AU2003201741A1 (en) 2002-01-09 2003-07-24 Yusuke Nakamura Cancer profiles
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
CA2487811A1 (en) 2002-05-27 2003-12-04 Per Sonne Holm Use of adenoviruses replicating in a yb-1 dependent manner for the treatment of tumors
US9388427B2 (en) * 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
WO2004050844A2 (en) * 2002-12-02 2004-06-17 Biovec Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20050106124A1 (en) * 2003-02-25 2005-05-19 Sehgal Lakshman R. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
JP4668919B2 (ja) * 2003-10-08 2011-04-13 サノフィ パストゥール インコーポレイテッド 修飾ｃｅａ／ｂ７ベクター
WO2005051430A1 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
WO2005086922A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US8470315B2 (en) * 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US20080305181A1 (en) * 2004-04-20 2008-12-11 Kontos Christopher D Compositions and Methods for Treatment of Vascular Grafts
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
WO2006042017A2 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
KR100984602B1 (ko) * 2004-11-18 2010-09-30 고쿠리츠다이가쿠호진 히로시마다이가쿠 유전자 증폭에 의해 형성된 반복서열로부터, 발현이 억제된단백질을 발현시키는 방법, 키트, 및 형질전환체
WO2007046826A2 (en) * 2004-12-01 2007-04-26 The Regents Of The University Of Michigan Compositions and methods for regulating cardiac performance
EP2110667A1 (de) 2005-01-20 2009-10-21 University Of Rochester Mit Thioredoxin interagierendes Protein (TXNIP) als Regulator der Gefäßfunktion
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
HUE031122T2 (en) 2005-10-31 2017-07-28 Oncomed Pharm Inc Preparations and methods for the treatment of cancer based on human FZD receptors
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
US20100159450A1 (en) 2006-06-23 2010-06-24 Susanne Wagner Dpyd gene variants and use thereof
EP2049151A4 (de) 2006-07-17 2010-03-24 Quintessence Biosciences Inc Verfahren und zusammensetzungen zur behandlung von krebs
US20080261216A1 (en) * 2006-09-08 2008-10-23 The Regents Of The University Of Michigan HERV Group II Viruses In Lymphoma And Cancer
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
US8148147B2 (en) * 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
EP3018216B1 (de) 2007-07-06 2018-09-12 The Regents Of The University Of Michigan Rezidivierende genfusionen bei prostatakrebs
EP2179292B1 (de) 2007-08-16 2012-11-28 The Regents of the University of Michigan Metabolomische profilierung von prostatakrebs
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
US8193151B2 (en) * 2008-04-25 2012-06-05 Northwestern University Methods for treating atrial or ventricular arrhythmias
US8518884B2 (en) 2008-04-25 2013-08-27 Northwestern University Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
JP2012504423A (ja) 2008-10-01 2012-02-23 クインテッセンス バイオサイエンシズ，インコーポレーテッド 治療用リボヌクレアーゼ
WO2010081001A2 (en) 2009-01-09 2010-07-15 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
WO2010107991A2 (en) 2009-03-18 2010-09-23 Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
EA032675B1 (ru) 2009-06-10 2019-07-31 Нью-Йорк Юниверсити Способ и композиции для лечения болезни альцгеймера и других таупатий
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011116209A2 (en) 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
EP2552953B1 (de) 2010-04-01 2017-05-17 OncoMed Pharmaceuticals, Inc. Frizzled-bindende stoffe und ihre verwendungen
US20130344053A1 (en) 2010-12-28 2013-12-26 University Of Rochester Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
CA2840856C (en) 2011-07-06 2017-09-19 Sykehuset Sorlandet Hf Egfr targeted therapy
HUE051021T2 (hu) 2011-09-07 2021-01-28 Sinai School Medicine Ceramidáz és sejtek differenciálódása
US9265813B2 (en) 2011-10-27 2016-02-23 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
US9694050B2 (en) 2012-10-21 2017-07-04 University Of Rochester THY1 (CD90) as a novel therapy to control adipose tissue accumulation
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
EP2911691B1 (de) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln
WO2014095088A1 (en) 2012-12-21 2014-06-26 Sykehuset Sørlandet Hf Egfr targeted therapy of neurological disorders and pain
WO2014121196A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP2992112B1 (de) 2013-04-22 2020-06-03 Icahn School of Medicine at Mount Sinai Mutationen in pdgfrb und notch3 als ursachen für autosomale dominante infantile myofibromatose
WO2015066190A1 (en) 2013-10-29 2015-05-07 President And Fellows Of Harvard College Methods and compositions for inhibting oxidative stress
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
US11352642B2 (en) 2015-01-09 2022-06-07 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
US10377801B2 (en) 2015-11-04 2019-08-13 Northwestern University Amelioration of chronic kidney disease
US11273151B2 (en) 2015-11-04 2022-03-15 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
US10669320B2 (en) 2015-11-18 2020-06-02 The Regents Of The University Of Michigan Mps1 and KNL1 phosphorylation system
KR20180102108A (ko) * 2016-02-05 2018-09-14 난트 홀딩스 아이피, 엘엘씨 재조합 CXADR 발현을 위한 조성물 및 방법 (Compositions And Methods For Recombinant CXADR Expression)
US11246868B2 (en) 2016-04-26 2022-02-15 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
US20200282032A1 (en) 2016-05-27 2020-09-10 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
CA2971303A1 (en) 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
WO2018013509A1 (en) 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
WO2018140630A1 (en) 2017-01-25 2018-08-02 Northwestern University Autophagy inducers for treatment of cns conditions
US10815484B2 (en) 2017-11-22 2020-10-27 The Regents Of The University Of Michigan Compositions and methods for treating cancer
US11573230B2 (en) 2018-01-26 2023-02-07 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
US20210046177A1 (en) 2018-01-26 2021-02-18 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
US20220184232A1 (en) * 2019-03-25 2022-06-16 The Regents Of The University Of California Methods of treating tnni3-mediated cardiomyopathy
EP3976075A4 (de) * 2019-05-30 2023-08-16 Gritstone bio, Inc. Modifizierte adenoviren
CN114051413A (zh) 2019-06-28 2022-02-15 河谷细胞有限公司 增强吞噬作用而不引起炎症的药物组合物
KR102371663B1 (ko) * 2020-01-21 2022-03-04 코오롱생명과학 주식회사 아데노바이러스 벡터
WO2021183717A1 (en) 2020-03-11 2021-09-16 Nantcell, Inc. Proteinaceous therapeutics
WO2021202325A1 (en) * 2020-03-28 2021-10-07 Greffex, Inc. Maintaining dna fragments in eukaryotic cells, approaches and uses
WO2021211691A1 (en) 2020-04-14 2021-10-21 Immunitybio, Inc. Yeast lysate covid-19 vaccine
CA3184734A1 (en) 2020-08-11 2022-02-17 Musculoskeletal Transplant Foundation Method for treating cardiac conditions with placenta-derived compositions
WO2022034523A1 (en) 2020-08-13 2022-02-17 Immunitybio, Inc. Phagocytosis-inducing compounds and methods of use
CN117715929A (zh) 2021-07-29 2024-03-15 南特细胞公司 用于预防和治疗病毒感染和癌症的经修饰的t细胞受体
EP4335870A1 (de) 2022-09-06 2024-03-13 NantCell, Inc. Peptidtherapeutika gegen das sars-cov-2-spike-protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
AU704391B2 (en) * 1994-10-28 1999-04-22 Trustees Of The University Of Pennsylvania, The Improved adenovirus and methods of use thereof
DE69628744D1 (de) 1995-04-17 2003-07-24 Univ Texas System Austin Board Adenovirus helfervirus system
AU2319497A (en) * 1996-03-07 1997-09-22 Regents Of The University Of California, The Helper-free, totally defective adenovirus for gene therapy

Also Published As

Publication number Publication date
EP0935648A4 (de) 2004-11-17
AU5152998A (en) 1998-05-15
US6063622A (en) 2000-05-16
US6451596B1 (en) 2002-09-17
ATE466931T1 (de) 2010-05-15
WO1998017783A1 (en) 1998-04-30
US6057158A (en) 2000-05-02
US5994132A (en) 1999-11-30
EP0935648A1 (de) 1999-08-18
US6083750A (en) 2000-07-04
EP0935648B1 (de) 2010-05-05

Similar Documents

Publication Publication Date Title
DE69739870D1 (de) Verbesserte adenovirusvektoren
Parks et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal
Sandig et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
DE919627T1 (de) Defektive Adenoviren und entsprechende transkomplementante Zelllinien
DE69820450D1 (de) Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
CA2391591A1 (en) Permanent amniocyte cell line, the production thereof and its use for producing gene transfer vectors
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
WO2000012740A3 (en) Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
DE3471688D1 (en) Dna vectors and their use in recombinant dna technology
WO1998027204A3 (en) AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
EP0851769A4 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
DE69628744D1 (de) Adenovirus helfervirus system
CA2047290A1 (en) Recombinant marek's disease virus
BR9711998A (pt) Herpesvìrus saimiri como vetor viral.
DK0843731T3 (da) Adenovirusvektorer til genterapi
Kaplan et al. Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes
WO1999057284A3 (en) Attenuated influenza viruses
WO2000022136A3 (en) Recombinant e1a deleted adenoviral vectors
WO2000029573A3 (en) Adenoviral vectors
Orum et al. Sequence and proposed secondary structure of the Tetrahymena thermophila U3-snRNA.
EP1015560A4 (de) Veränderte, kleine rna-viren
BR0318026A (pt) Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition